Our laboratory utilized two
methods to produce the anti-CD19 i
mmunotoxincontaining a single-chain Fv (scFv) FVS191 and a ricin A chain (RTA). The first
methodproduced the reco
mbinant proteinFVS191CDRTA fro
m a fusing gene containing sequences encoding FVS191,catheptsin D proteinasedigestion site (CD), and RTA. FVS191CDRTA did not show CD19antigen binding and cytotoxicactivity. The second
method generated a disulfide-linkedFVS191cys-dgRTA fro
m a FVS191cys, theFVS191 with an additional C-ter
minal cysteine, and a deglycosylated RTA(dgRTA). The for
mationof FVS191cys-dgRTA is efficient; up to 70% of the proteinsparticipating in the reaction had for
medFVS191cys-dgRTA when the
molar ratio of FVS191cys to dgRTA was 1:1.A co
mpetitive ELISAassay indicated that FVS191cys-dgRTA and the parental
monoclonalantibody B43 possessedco
mparable CD19 binding abilities. The protein synthesisinhibition assay revealed that FVS191cys-dgRTA was toxic to CD19 positive cell lines, but it was less potent thanthe intact antibody-conjugatedB43-dgRTA, which had an IC
50 = 2 ×10
-11 M.
125I-Labeled FVS191and
125I-labeled B43 wereinternalized by Nal
m-6 cells at 37
mages/entities/deg.gif">C as de
monstrated byinternalization studies; this result indicatesthat cross-linking of CD19 antigen is not required for the endocytosisof CD19 and raises the possibilitythat the lower cytotoxity of FVS191cys-dgRTA is not due to the
monovalent binding of CD19 byFVS191cys-dgRTA. Our study with anti-CD19 scFv i
mmunotoxinindicates that the for
mation of adisulfide-linked scFv i
mmunotoxin is an alternative to the reco
mbinant
method of producing scFvi
mmunotoxin.